Ginkgo Bioworks Holdings, Inc.
DNA
$9.34
-$0.56-5.66%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.13% | 25.21% | 13.76% | -9.71% | -30.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.13% | 25.21% | 13.76% | -9.71% | -30.81% |
| Cost of Revenue | 18.67% | 33.02% | 16.07% | -17.51% | -46.48% |
| Gross Profit | -25.57% | 23.29% | 13.20% | -7.57% | -25.68% |
| SG&A Expenses | -25.47% | -30.70% | -28.59% | -30.92% | -33.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.10% | -39.53% | -30.71% | -27.85% | -30.81% |
| Operating Income | 39.52% | 57.08% | 44.08% | 34.08% | 30.82% |
| Income Before Tax | 47.81% | 64.79% | 44.67% | 38.68% | 25.02% |
| Income Tax Expenses | -47.44% | -89,600.00% | -245.90% | -574.65% | 97.60% |
| Earnings from Continuing Operations | 47.86% | 64.89% | 44.71% | 38.73% | 23.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.86% | 64.89% | 44.71% | 38.73% | 23.98% |
| EBIT | 39.52% | 57.08% | 44.08% | 34.08% | 30.82% |
| EBITDA | 43.27% | 60.84% | 46.66% | 34.57% | 30.09% |
| EPS Basic | 51.74% | 67.53% | 48.34% | 42.17% | 27.78% |
| Normalized Basic EPS | 41.32% | 60.20% | 47.59% | 38.18% | 32.66% |
| EPS Diluted | 51.76% | 67.54% | 48.38% | 42.20% | 28.05% |
| Normalized Diluted EPS | 41.30% | 60.19% | 47.58% | 38.17% | 32.65% |
| Average Basic Shares Outstanding | 7.57% | 7.74% | 7.63% | 6.75% | 6.17% |
| Average Diluted Shares Outstanding | 7.54% | 7.72% | 7.61% | 6.72% | 6.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |